FI962613A0 - Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi - Google Patents

Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Info

Publication number
FI962613A0
FI962613A0 FI962613A FI962613A FI962613A0 FI 962613 A0 FI962613 A0 FI 962613A0 FI 962613 A FI962613 A FI 962613A FI 962613 A FI962613 A FI 962613A FI 962613 A0 FI962613 A0 FI 962613A0
Authority
FI
Finland
Prior art keywords
inactivation
detergent
determining
capacity
treatment
Prior art date
Application number
FI962613A
Other languages
English (en)
Swedish (sv)
Other versions
FI962613A (fi
FI105076B (fi
Inventor
Johann Eibl
Friedrich Elsinger
Yendra Linnau
Guenther Woeber
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to FI962613A priority Critical patent/FI105076B/fi
Publication of FI962613A0 publication Critical patent/FI962613A0/fi
Publication of FI962613A publication Critical patent/FI962613A/fi
Application granted granted Critical
Publication of FI105076B publication Critical patent/FI105076B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Detergent Compositions (AREA)
FI962613A 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi FI105076B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AT123791 1991-06-20
AT0123791A AT402891B (de) 1991-06-20 1991-06-20 Verfahren zur herstellung eines inaktivierten blutproduktes
FI922850 1992-06-18
FI922850A FI98491C (fi) 1991-06-20 1992-06-18 Menetelmä virusinaktivoidun verituotteen valmistamiseksi
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
FI962613 1996-06-24

Publications (3)

Publication Number Publication Date
FI962613A0 true FI962613A0 (fi) 1996-06-24
FI962613A FI962613A (fi) 1996-06-24
FI105076B FI105076B (fi) 2000-06-15

Family

ID=3509572

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922850A FI98491C (fi) 1991-06-20 1992-06-18 Menetelmä virusinaktivoidun verituotteen valmistamiseksi
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI922850A FI98491C (fi) 1991-06-20 1992-06-18 Menetelmä virusinaktivoidun verituotteen valmistamiseksi

Country Status (14)

Country Link
US (2) US5614405A (fi)
EP (2) EP0519901B1 (fi)
JP (2) JP3011819B2 (fi)
AT (2) AT402891B (fi)
AU (1) AU648414B2 (fi)
CA (1) CA2071567C (fi)
CZ (2) CZ285115B6 (fi)
DE (1) DE59209735D1 (fi)
DK (1) DK0519901T3 (fi)
ES (1) ES2137178T3 (fi)
FI (2) FI98491C (fi)
HU (2) HU213470B (fi)
NO (2) NO305933B1 (fi)
SK (1) SK281412B6 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
ES2118386T3 (es) 1993-02-09 1998-09-16 Octapharma Ag Procedimiento para la inactivacion de virus que no estan provistos de envolventes lipidicas.
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
DE19617369A1 (de) * 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US5837519A (en) * 1996-11-21 1998-11-17 Bayer Corporation Dry-heat viral inactivation under controlled moisture conditions
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT406120B (de) 1997-08-28 2000-02-25 Immuno Ag Gewebekleber
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
CA2362513C (en) 1999-02-12 2011-04-26 Baxter Aktiengesellschaft A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
AT410218B (de) 1999-08-20 2003-03-25 Baxter Ag Verfahren zur herstellung eines qualitätsgesicherten pools biologischer proben
FR2806910B1 (fr) * 2000-04-03 2003-01-24 Dolisos Lab Procede d'inactivation virale de solutions hydro-alcooliques
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US7753945B2 (en) * 2003-01-17 2010-07-13 Gore Enterprise Holdings, Inc. Deployment system for an endoluminal device
ES2403357T3 (es) 2003-12-11 2013-05-17 Isto Technologies Inc. Sistema de cartílago particulado
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20090012629A1 (en) 2007-04-12 2009-01-08 Isto Technologies, Inc. Compositions and methods for tissue repair
JP5555626B2 (ja) 2007-08-13 2014-07-23 バクスター・インターナショナル・インコーポレイテッド 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
CN110343171A (zh) 2012-02-29 2019-10-18 百深公司 周围神经的IgG刺激髓鞘再生
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
KR102238133B1 (ko) * 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5714653B2 (fi) * 1974-06-21 1982-03-25
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
ATE36457T1 (de) * 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
AU2251288A (en) * 1987-05-15 1988-12-06 Alan I. Rubinstein Sequential improved method for treatment of human blood- clotting factor products
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
DE3730533A1 (de) * 1987-09-11 1989-03-30 Biotest Pharma Gmbh Verfahren zur sterilisation von plasma oder plasmafraktionen
AT391809B (de) * 1988-01-12 1990-12-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
DE3878227D1 (de) * 1988-05-27 1993-03-18 Centre Regional De Transfusion Verfahren zur herstellung eines hochreinen, virusfreien antihaemophiliefaktors mittels chromatographie.
AT397203B (de) * 1988-05-31 1994-02-25 Immuno Ag Gewebeklebstoff
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
FR2644476A1 (fr) * 1989-03-15 1990-09-21 Sainte Agathe Nicolas De Procede de detection et/ou d'identification de micro-organismes vivants par vibrometrie
JP3297433B2 (ja) * 1989-06-15 2002-07-02 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド ウイルスで汚染された薬理組成物中のウイルスの不活性化方法
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
JPH06507078A (ja) * 1992-02-10 1994-08-11 バクスター、インターナショナル、インコーポレイテッド ウイルス汚染について血液単位を試験するための方法
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
FR2841484B1 (fr) * 2002-06-26 2004-09-10 Boucq De Beaudignies Ghisla Le Dispositif et procede de filtration de l'air et des gaz avec regeneration des particules captees

Also Published As

Publication number Publication date
ATA123791A (de) 1997-02-15
DK0519901T3 (da) 2000-02-14
HUT61477A (en) 1993-01-28
EP0519901A3 (en) 1993-05-19
FI922850A (fi) 1992-12-21
SK190292A3 (en) 1995-05-10
DE59209735D1 (de) 1999-09-23
FI98491C (fi) 1997-07-10
EP0519901B1 (de) 1999-08-18
CZ285552B6 (cs) 1999-09-15
HU211545A9 (en) 1995-12-28
JPH05186358A (ja) 1993-07-27
FI962613A (fi) 1996-06-24
US5614405A (en) 1997-03-25
EP0519901A2 (de) 1992-12-23
FI105076B (fi) 2000-06-15
ES2137178T3 (es) 1999-12-16
CA2071567C (en) 2003-04-29
HU213470B (en) 1997-06-30
NO973996L (no) 1992-12-21
ATE183396T1 (de) 1999-09-15
CZ190292A3 (en) 1993-01-13
US5864016A (en) 1999-01-26
JP2000080042A (ja) 2000-03-21
AU1830692A (en) 1992-12-24
FI922850A0 (fi) 1992-06-18
JP3011819B2 (ja) 2000-02-21
HU9201986D0 (en) 1992-09-28
AU648414B2 (en) 1994-04-21
NO305933B1 (no) 1999-08-23
AT402891B (de) 1997-09-25
CA2071567A1 (en) 1992-12-21
SK281412B6 (sk) 2001-03-12
NO973996D0 (no) 1997-09-01
NO922420D0 (no) 1992-06-19
EP0882455A1 (de) 1998-12-09
FI98491B (fi) 1997-03-27
JP3512163B2 (ja) 2004-03-29
NO922420L (no) 1992-12-21
CZ285115B6 (cs) 1999-05-12

Similar Documents

Publication Publication Date Title
FI962613A0 (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE90573T1 (de) Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung.
ATE220927T1 (de) Inaktivierung von prionen in bindegewebematerialen
NO831304L (no) Fremgangsmaate for inaktivering av virus i blodplasma
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
DE69212254D1 (de) Haarpflegemittel
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
DE3786838D1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern.
ES2006632A6 (es) Procedimiento de tratamiento termico de fibrinogeno.
FI892769A0 (fi) Foerfarande foer inaktivering av den rekombinanta dna:n.
ES2059323T3 (es) Procedimiento para la produccion de una preparacion de inmunoglobulina pasteurizada.
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE3880533D1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
ATE125713T1 (de) Verfahren zur inaktivierung der biologischen aktivität von dna.
RU97106453A (ru) Способ обработки рук медицинского персонала, гнойных ран, инъекционных и операционных полей, а также стерилизации медицинского инструментария
ATE62599T1 (de) Verwendung einer loesung von alpha-chymotrypsin.
EP0250502A1 (en) PROCESS FOR INACTIVATING BLOOD VEHICLE HEAT-SENSITIVE PATHOGENIC VIRUSES IN IgG PREPARATIONS.
SU955690A1 (ru) Способ концентрирования вируса ящура
SU1331337A1 (ru) Способ дезактивации оборудования первых контуров яэу, выполненных из углеродистых и нержавеющих сталей